IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: Finally, the currently ongoing TIGER (CML V)-Study (NCT01657604) aims to investigate if nilotinib 600 mg BID monotherapy would be improved using low dose Peg-IFNα2b (30–50 μg/week) as an inducer of immunosurveillance.